Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2019-11-28 Major Shareholding Noti…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Holding(s) in Company TR-1: Standard form for notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document text explicitly contains the header "TR-1: Standard form for notification of major holdings" and is structured as a formal notification table detailing changes in voting rights and share ownership percentages for a specific issuer (Verona Pharma Plc) by a shareholder (Polar Capital LLP). This format is characteristic of regulatory filings related to significant ownership changes, which aligns directly with the definition of a Major Shareholding Notification (MRQ). The document is a specific regulatory disclosure, not a general announcement of a report (RPA/RNS) or a comprehensive financial report (10-K/IR).
2019-11-28 English
Verona Pharma plc: Grant of Options to PDMR
Director's Dealing Classification · 1% confidence The document announces the grant of 500,000 options to purchase ordinary shares to the CEO, Dr. Jan-Anders Karlsson, under an incentive award plan. It explicitly states that further information is provided in accordance with the requirements of the EU Market Abuse Regulation, followed by a detailed table titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.' This structure is characteristic of insider transaction reporting, specifically concerning executive dealings in company stock (options grant in this case). This directly matches the definition for Director's Dealing (DIRS).
2019-11-27 English
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
Director's Dealing Classification · 1% confidence The document explicitly details a purchase of ordinary shares by the Chairman of the Company, Dr. David Ebsworth. It includes specific transaction details (price, volume, date) and is structured according to the requirements for 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' under the EU Market Abuse Regulation. This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the Director's Dealing category.
2019-11-18 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document explicitly contains the header "RNS Number : 4562T" and details a "TR-1: Standard form for notification of major holdings". This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the core content is a specific regulatory filing about share ownership changes, making MRQ the most precise classification over the general RNS fallback.
2019-11-14 English
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
Director's Dealing Classification · 1% confidence The document explicitly details a transaction where the Chairman of Verona Pharma plc, Dr. David Ebsworth, purchased a significant number of ordinary shares. It includes specific details required by the EU Market Abuse Regulation regarding transactions by persons discharging managerial responsibilities (PDMRs). This content directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The filing type code 'DIRS' is the appropriate classification.
2019-11-14 English
Verona Pharma to Present at Jefferies 2019 London Healthcare Conference
Regulatory Filings Classification · 1% confidence The document is a press release dated November 13, 2019, announcing that the CEO of Verona Pharma will present at the Jefferies 2019 London Healthcare Conference on November 20-21, 2019. This content is an announcement about executive participation in an external investor event, which is a form of corporate communication aimed at investors. It is not a formal regulatory filing (like 10-K, IR, or ER), nor is it a transcript (CT) or a formal presentation deck (IP). It is best classified as a general announcement related to investor relations activities, which fits best under the 'Regulatory Filings' (RNS) category as a general corporate announcement, or potentially 'Investor Presentation' (IP) if it were the presentation itself, but since it's just an announcement of attendance, RNS is the most appropriate fallback for non-specific investor news.
2019-11-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.